Description
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed to replicate the effects of epithalamin, a natural protein produced by the pineal gland. Its primary role is to activate telomerase, the enzyme responsible for preserving telomere length—the protective caps on chromosomes that naturally shorten with age and cellular division.
By stimulating telomerase activity, Epitalon is believed to:
- Support healthy cellular aging
- Promote immune system balance
- Regulate melatonin secretion and circadian rhythm
- Protect cells from oxidative stress
Benefits of Epitalon :
Epitalon’s benefits extend beyond general wellness — it targets the root causes of cellular aging and hormonal decline. For beginners exploring longevity-enhancing peptides, Epitalon offers a wide range of systemic support backed by emerging scientific literature.
- Supports Telomere Length and Cellular Longevity
- Improves Sleep Through Melatonin Regulation
- Antioxidant Effects and Oxidative Stress Protection
Epitalon Dosage and Cycle Strategy :
If you’re new to Epitalon, proper dosing is crucial for achieving benefits while minimizing unnecessary risks. Fortunately, Epitalon is one of the more well-tolerated peptides, with human trials dating back decades. While optimal dosing for anti-aging in humans is still under investigation, most protocols are derived from animal studies and clinical use in Eastern Europe.
Common Dosage Protocol :
Dose: 5–10 mg total per cycle (divided into daily doses)
Daily Injection: 1–2 mg per day
Route: Subcutaneous (SubQ) injection
Duration: 10–20 days per cycle
Frequency: 1–2 times per year (spring and fall, or every 6 months)
“Ukrainian” Protocol :
Day 1 : 10mg
Day 5 : 10mg
Day 9 : 10mg
Day 13 : 10mg
Day 17 : 10mg
Example Beginner Protocol :
Day 1–10: 2 mg daily, Subcutaneous, preferably in the evening
Optional Extension: Continue for up to 20 days if tolerated well
Cycle Off: 6 months before repeating
This protocol reflects what has been used in aging research and clinical longevity programs in Russia, where Epitalon has been administered in geroprotective trials for decades with relatively few adverse events.
